Amanta Healthcare Reports Insider Purchase of 15,675 Equity Shares by Director's Relative
Amanta Healthcare Limited disclosed that Ms. Dypal Jain, immediate relative to Director Shri Nitin Jain, purchased 15,675 equity shares through open market transactions between March 19-24, 2026, valued at ₹15.01 lakh. The transactions were executed on NSE and BSE exchanges, increasing her total shareholding to 15,676 shares (0.04% of equity capital). The company submitted the required SEBI insider trading disclosure on March 26, 2026.
*this image is generated using AI for illustrative purposes only.
Amanta Healthcare Limited has submitted a disclosure under Regulation 7(2) read with Regulation 6(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015, regarding an open market purchase of equity shares by an insider.
Transaction Details
Ms. Dypal Jain, who is an immediate relative to Director Shri Nitin Jain, acquired 15,675 equity shares of the company through open market purchases conducted between March 19, 2026, and March 24, 2026.
| Parameter: | Details |
|---|---|
| Purchaser: | Ms. Dypal Jain |
| Relationship: | Immediate relative to Director Shri Nitin Jain |
| Number of Shares: | 15,675 |
| Transaction Value: | ₹15.01 lakh |
| Transaction Period: | March 19-24, 2026 |
| Exchanges: | NSE and BSE |
Shareholding Position
Prior to this transaction, Ms. Dypal Jain held 1 equity share representing a negligible percentage of the company's total shareholding. Following the acquisition of 15,675 additional shares, her total shareholding has increased to 15,676 equity shares, representing 0.04% of the company's equity capital.
| Shareholding Details: | Before Transaction | After Transaction |
|---|---|---|
| Number of Shares: | 1 | 15,676 |
| Percentage Holding: | Negligible % | 0.04% |
| Security Type: | Equity Shares | Equity Shares |
Regulatory Compliance
The company received the disclosure in Form 'C' pursuant to Regulation 7(2) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, dated March 25, 2026. The disclosure was submitted to both BSE Limited and National Stock Exchange of India Limited on March 26, 2026, by Company Secretary and Compliance Officer Nikhita Dinodia.
The transaction represents a market purchase executed through regular trading mechanisms on both major Indian stock exchanges, demonstrating compliance with insider trading disclosure requirements under SEBI regulations.
Historical Stock Returns for Amanta Healthcare
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +2.14% | +9.59% | +4.97% | -20.73% | -23.76% | -23.76% |
What strategic initiatives or growth prospects might have motivated this insider family member to significantly increase their stake in Amanta Healthcare?
Will other promoter family members or directors follow suit with similar equity purchases in the coming quarters?
How might this insider buying activity influence retail investor sentiment and trading volumes for Amanta Healthcare shares?
18
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
